Program characteristics | Program outcomes | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
First author, year of publication | Calendar year of data collection | Population | Country and HCV prevalence according to CDC[23] | Setting of screening | Duration of screening program | Other tests | Pre-screening selection | Media activities | Screening uptake and anti-HCV prevalence (95% CI) | Risk profile of identified HCV cases/Risk factors associated with HCV | Follow-up of HCV-infected individuals |
Meky et al. 2006 [55] | 2002-2005 | General population | Egypt (6.6%): Two rural villages in the Nile Delta | Community health clinic and private clinics for acute cases | 29 months | HAV, HBV, HEV, CMV, Epstein-Barr | Only those with symptoms and ALT levels = > 2 times the upper limit of normal were tested | Yes | Scr. uptake: NR Prevalence: 78.7% (37/47; 95% CI:65.1-88.0* | NR | At 2 and 6 months following initial examination, follow-up testing was done to confirm or reclassify the diagnosis (i.e., viral clearance or persistent infection). No data was reported about medical follow-up of chronically infected patients. |
Outcomes: RNA rate: 70.2% (33/37) Start treatment: NR SVR: NR | |||||||||||
Chen et al. 2007 [58] | 1996-2005 | General population aged ≥18 yrs | Taiwan (2.1% a): throughout the country | Outreach community based screening | 10 years | HBV, ALT, AST | No | Yes | Scr. uptake: NR Prevalence: 4.4% (6904/157720; 95% CI: 4.3-4.5)** | NR | Patients were requested to return to the collaborating hospitals for subsequent management (results were not reported). |
Outcomes: RNA rate: NR Start treatment: NR SVR: NR | |||||||||||
Aslam & Aslam 2001 [57] | 2000 | General population | Pakistan (6.6%): Lahore and Gujranwala | City screening program | NR | None | No | Yes | Scr. uptake: Lahore: 0.01% 488/5063500 Gujranwala: 0.2% (1922/1124800) Prevalence: Lahore: 16% (78/488; 95% CI:13.0-19.5) Gujranwala: 23.8% (458/1922; 95% CI: 22.0-25.8)* | Listed risk factors: - Blood transfusion - Surgery/dental work - Multiple factors - Mostly other, non-specified risk factors | Patients were informed about the possibility of eradication of the virus, and treatment in its early stages (further data not provided) Outcomes: RNA rate: NR Start treatment: NR SVR: NR |
Lu et al. 1998 [56] | 1994 | General population <16 yrs | Taiwan (2.1% a): Paisha Township, Penghu Islets | Kindergartens and schools | 1 month | HBV | No | NR | Scr. uptake: 93.6% (1164/1243) Prevalence: 0.9% (11/1164; 95% CI: 0.5-1.7) overall* 3–6 yrs: 0% 7–12 yrs: 0.8% 13–15 yrs: 1.9% | Listed risk factors: - Surgery - Intramuscular injection - Intravascul ar injection, - Intravascular infusion | All anti-HCV positive children were followed annually for 2 years with upper abdominal sonography, AST, ALT, anti-HCV and HCV RNA. No data was reported about medical follow-up of chronically infected children. |
 |  |  |  |  |  |  |  |  |  |  | Outcomes: RNA rate: 27.3% (3/11) Start treatment: NR SVR: NR |